The 2nd International Electronic Conference on Biomedicines
Part of the International Electronic Conference on Biomedicines series
1–31 Mar 2023
Therapeutic Targets, Therapeutic Strategies, Naturally Driven Biomedicines, Pharmaceuticals, Biopharmaceutical Products
- Go to the Sessions
-
- S1. RNA Processing and Human Diseases
- S2. Molecular Mechanisms of Neurodegeneration
- S3. Extracellular Vesicles for Biomarker Discovery
- S4. Medicinally Active Plants and Phytochemicals
- S5. Wound Healing
- S6. Musculoskeletal Tissue Regeneration
- S7. Nutraceuticals as Adjuvant Therapeutics
- S8. Frontiers of biomedicine in SARS-CoV-2
- S9. Gastrointestinal Cancer
- S10. Immune System, Tumor Immunology and Autoimmune Disease
- Event Details
-
- ECB 2023 is closed. Thank you for your participation.
- Welcome from the Chairs
- Live Sessions Information
- Live Session Program
- Live Session Recordings
- Event Chairs
- Session Chairs
- Event Speakers
- Sessions
- Instructions for Authors
- List of Accepted Submissions
- Event Awards
- Conference Secretariat
- Sponsors and Partners
- Events in series ECB
ECB 2023 is closed. Thank you for your participation.
The recordings of ECB 2023 live sessions are available at: https://ecb2023.sciforum.net/#recordings
All participants of ECB 2023 are welcome to submit an extended full paper to the Special Issue "Selected Papers in the 2nd International Electronic Conference on Biomedicines (ECB 2023)" of the journal Biomedicines, with a 20% discount on the Article Processing Charges.
The ECB 2023 award winners have been announced at https://ecb2023.sciforum.net/#awards
Welcome from the Chairs
Dear Colleagues,
It is our pleasure to invite you to join the 2nd International e-Conference on Biomedicines in 2023 (ECB 2023) that is hosted online by: https://ecb2023.sciforum.net.
ECB 2023 will present the latest research related to all aspects of research on human health and diseases, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics of interest include, but are not limited to:
1. Frontiers of biomedicine in SARS-CoV-2
2. RNA Processing and Human Diseases
3. Extracellular Vesicles for Biomarker Discovery
4. Biomedicine in Cardiovascular Diseases
5. Medicinally Active Plants and Phytochemicals
6. Molecular Mechanisms of Neurodegeneration
7. Immune System, Tumor Immunology and Autoimmune Disease
8. Gut Microbiota and Biomedicine
9. Obesity and Metabolic Diseases
10. Nutraceuticals as Adjuvant Therapeutics
11. Organ-on-chip and Precision Medicine
12. Mitochondrial Diseases
13. Gastrointestinal Cancer
14. Regulation of Protein Synthesis in Health and Disease
15. Musculoskeletal Tissue Regeneration
16. Wound Healing
17. Peptide-Based Piezoelectric Materials
18. Viral Hepatitis and Transition
19. Chronic and Acute Kidney Injury – Prevention and Treatment
20. Nanomedicine, Combination Cancer Therapy and Immunotherapy
ECB 2023 seeks to fulfill the need of academics to gather together to share results and ideas by offering a completely digital (online) method of running this scientific conference. ECB 2023 will allow its participants to share their latest research results and receive instant feedback from their peers throughout the world through online forums. ECB 2023 will serve as a platform for advancing research in biomedicines. The greatest part is that there is no cost to participate in ECB 2023!
All submitted abstracts will be evaluated by the conference peer review committee. Upon acceptance, authors will contribute an extended abstract for the conference proceedings and a slide presentation of their work. The authors with outstanding contributions will be invited to submit full manuscripts for potential publication in the Biomedicines journal (https://www.mdpi.com/journal/biomedicines).
We hope you will choose to be a part of this exciting conference and present your most transformative research on biomedicines.
Prof. Dr. Jun Lu
Auckland University of Technology, New Zealand
Dr. Allan Stensballe
Aalborg University, Denmark
Follow the conference organizer on Social Media
Live Sessions Information
The live sessions are free of charge. The authors who submit submissions to ECB 2023 will have priority for registration (with no extra cost) to the live online sessions with our keynote speakers. If it is not completely full, registration will be open for unregistered participants. Registrations with academic institutional email addresses will be prioritized. The number of participants in the live session is limited but the recording will be made available on Sciforum shortly afterward.
We are pleased to invite you to subscribe to our conference so that you can receive email notifications when the live session program is online and open online discussions.
Live Session Program
Live Session 1
2 March 2023
10:00 am CET
Session Chair: Dr. Giuseppina Catanzaro
|
Presentation Topic |
Time (CET) |
Dr. Giuseppina Catanzaro |
Introduction |
10:00am-10:10am |
Dr. Giuseppina Catanzaro |
MicroRNAs in pediatric low grade gliomas |
10:10am-10:40am |
Irina Pronina |
EXPERIMENTAL IDENTIFICATION OF ABERRANLY EXPRESSED LONG NON-CODING RNAS IN BREAST CANCER |
10:40am-11:05am |
Live Session 2
3 March 2023
Time: 1:30 pm CET
Session Chair: Dr. Krisztina Nikovics
Speaker |
Presentation Topic |
Time (CET) |
Dr. Krisztina Nikovics |
Introduction |
1:30pm-1:40pm |
Dr. Krisztina Nikovics |
In situ identification of both IL-4 and IL-10 cytokines interactions with their specific receptors during tissue regeneration |
1:40pm-2:10pm |
Dr. Helene Boeuf |
Understanding the physiology of teeth-derived stem cells towards regenerative medicine purposes |
2:10pm-2:40pm |
Dr. Frédéric Velard |
Ion doping as a promising way forward to control host response to bioceramics |
2:40pm-3:10pm |
Dr. Diane Riccobono |
Treatment of irradiated muscles by cell therapy: from macroscopic wound healing to biological actors identification |
3:10pm-3:30pm |
Nicolas Jullien |
A new murine highly localized high-dose muscle radiation model as a tool to develop innovative countermeasures to treat radio-induced muscular lesions |
3:30pm-3:45pm |
Tatiana Lopez |
Role of oxidative stress and macrophages on tissue regeneration and inflammation |
3:45pm-4:00pm |
Live Session 3
15 March 2023
Time: 1:30 pm CET
Session Chair: Dr. Noemi Rotllan Vila
|
Presentation Topic |
Time (CET) |
Dr. Noemi Rotllan Vila |
Introduction |
1:30pm-1:40pm |
Dr. Noemi Rotllan Vila |
pHLIP: Novel therapeutic inhibition of miRNAs in an atherosclerosis pre-clinical model |
1:40pm-2:10pm |
Dr. Sonia Benítez González |
The effect of a modified LDL, called electronegative LDL (LDL(-)), on cardiomyocytes |
2:10pm-2:40pm |
Live Session 4
22 March 2023
Time: 1:30 pm CET
Session Chair: Dr. Allan Stensballe
|
Presentation Topic |
Time (CET) |
Dr. Allan Stensballe |
Introduction |
1:30pm-1:40pm |
Prof. Dr. M. R. Mozafari | Biomedical Applications |
1:40pm-2:10pm |
Sin Yee Yap |
Identification of serum protein in a depressed Chinese Malaysian university student: a case study |
2:10pm-2:25pm |
Rahat Ullah khan |
In vitro and in vivo effects of conventional and chitosan nanoparticles encapsulated miltefosine drugs for the treatment of cutaneous leishmaniasis |
2:25pm-2:40pm |
Ifeoma Felicia Chukwuma |
Modulatory Action of Phenolic-enriched/Combretum paniculatum/ Vent Ethanolic Extract on Oxidoinflammatory Anomalies in Experimental Animals |
2:40pm-2:55pm |
Tiago Azevedo |
Santolina chamaecyparissus L.: a brief overview of its medicinal properties |
2:55pm-3:10pm |
Marta García López |
GENERATION OF iPSC-DERIVED RGCs FOR MODELING DOMINANT OPTIC ATROPHY |
3:10pm-3:25pm |
Sara Khorami Sarvestani |
Cancer is associated with the emergence of placenta-reactive autoantibodies |
3:25pm-3:40pm |
Live Session 5
28 March 2023
10:00 am CEST
Session Chair: Dr. Stefano Bacci
|
Presentation Topic |
Time (CEST) |
Dr. Stefano Bacci |
Introduction |
10:00am-10:10am |
Dr. Stefano Bacci |
Neuroimmunomodulation in chronic wounds healing after treatment with photodynamic therapy: the Role of iNOS. |
10:10am-10:40am |
Dr. Montserrat Fernández-Guarino |
THE TRANSLATIONAL INSIGHT OF A CLINICIAN: THE NECCESITY OF IMPROVE THE COMMUNICATION WITH BASIC RESEARCHERS |
10:40am-11:10am |
Catarina S. Miranda |
Coaxial wet-spun fibers loaded with enzyme-inhibiting peptide for chronic wound care |
11:10am-11:25am |
Marta Teixeira |
Immobilization of Tiger 17 and pexiganan peptides onto PVA/CNC electrospun mats for an enhanced antimicrobial action and hemocompatibility in chronic wound treatments |
11:25am-11:40am |
Giada Magni |
Effects of short-wavelength blue light on fibroblasts. Experimental evidence in wound healing and cutaneous fibrosis |
11:40am-11:55am |
Francesca Rossi |
In vivo evidence of blue-LED-light photobiomodulation |
11:55am-12:10am |
Maria Luisa Hernandez |
Effects of RF currents on cytokines production in human keratinocytes |
12:10am-12:25am |
Live Session Recordings
Event Chairs
Professor Jun Lu gained PhD and MSc degrees from University of Auckland and BSc degree from East China Normal University. He joined AUT since 2009 and established the Biomedical Science major. He specialises in pharmacology, natural bioactive compounds/products, nutrition, metabolic diseases, cancer, and food science. He is currently situated in School of Science and School of Public Health and Interdisciplinary Studies. He is also a management team member of the Institute of Biomedical Technology.
Aalborg University, Aalborg, Denmark
Event Committee
brain histamine, eating behaviour, neurobiology of stress
Institut d’Investigació Biomèdica Sant Pau, Barcelona, Spain,
Instituto de Salud Carlos III, Madrid, Spain
Atherosclerosis, Lipid Metabolism, Vascular Biology, Mirnas Involved, Cholesterol metabolism
viral oncogenesis, innate antiviral response, coronaviruses, virus-host interaction
autoimmune diseases; liquid biopsy biomarkers; immunology; nanomaterial biocompatibility; flow cytometry; microvesicles
endothelial biomedicine, endothelium, lipid droplets, fluorescence microscopy, Raman spectroscopy
Cannabis, cancer, inflammatory bowel disease, pain
Cancer Pharmacology, Transcription Factors, Natural Products, Signal Transduction
biologics, soluble molecules, immune-mediated diseases, allergy, èharmacogenomics, vaccines
School of Engineering Technology, Purdue University Rm 187, Knoy Hall of Technology, USA
electroporation; electrochemotherapy; modeling and simulation of biological systems; electrical and electronics applications to medicine; healthcare; home health gadgets
Multi-modal drug delivery systems, Tumoroid drugs screening, Optical Imaging and photodynamic-based combination treatments, Photonanomedicines
functional MRI, brain-computer interface (BCI), electrical stimulation of nervous system, and neural network modelling
reactive oxygen species; redox homeostasis; electron transport chain; mitochondria; cancer metabolism; apoptosis; anticancer strategies; autophagy; drug development; viruses; angiogenesis
nuclear magnetic resonance; protein structures; allergens; transcription-translation coupling
skin tissue engineering, vascularisation, regenerative medicine, scarring
Nano-biomaterials, Cancer therapeutics, Nano-water technology, Drug delivery, Bio-catalysis, Nano-biosensors, Bio-separations
Musculoskeletal Pathology and Oncology Laboratory, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy
musculoskeletal diseases; bone cancer; chondrosarcoma; osteoarthritis; infrapatellar fat pad; meniscus; cartilage; synovial membrane; biomarkers; inflammation
Session Chairs
Dr. Giuseppina Catanzaro
Sapienza University of Rome, Rome, Italy
RNA Processing and Human Diseases
Dr. Masaru Tanaka
University of Szeged (ELKH-SZTE), Szeged, Hungary
Molecular Mechanisms of Neurodegeneration
Dr. Zoran Minic
University of Ottawa, Ottawa, Canada
Extracellular Vesicles for Biomarker Discovery
Prof. Dr. Shaker A. Mousa
Albany College of Pharmacy and Health Sciences, Rensselaer, USA
Medicinally Active Plants and Phytochemicals
Dr. Stefano Bacci
University of Florence, Florence, Italy
Wound Healing
Dr. Krisztina Nikovics
French Armed Forces Biomedical Research Institute, Brétigny-sur-Orge, France
Musculoskeletal Tissue Regeneration
Prof. Dr. Ciro Isidoro
Università del Piemonte Orientale, Novara, Italy
Nutraceuticals as Adjuvant Therapeutics
Dr. Sílvia Andreia Bento da Silva Sousa
Instituto Superior Técnico, Lisbon, Portugal
Frontiers of biomedicine in SARS-CoV-2
Dr. Ryota Niikura
Gastroenterological Endoscopy, Tokyo Medical University
Gastrointestinal Cancer
Dr. Jitka Petrlova
Department of Clinical Sciences, Division of Dermatology and Venereology, Lund University, Sweden
Immune System, Tumor Immunology and Autoimmune Disease
Keynote Speakers
Research unit of Histology and Embriology, Department of Biology, University of Florence, Italy
Dr. Stefano Bacci is a Professor of Cytology and Histology at the University of Florence and has resided, during his training, at the Schepens Eye Research Institute, Harvard Medical School, Boston (MA), USA. His main research concerns the understanding of the cellular mechanisms involved during wound healing in relation to different type of treatments. This research field has also led him to resolve important questions on the vitality of the lesion by proposing methods that are considered important in the forensic field. He is the author of more than 100 articles within his research sector, including publications of high scientific impact. For other related information, please see the following web page: https://sciprofiles.com/profile/915428.
Department of Medical Sciences, Division of Internal Medicine and Chronobiology Laboratory, Fondazione IRCCS Casa Sollievo della Sofferenza, Italy
Altered regulation of the circadian gene ARNTL in colorectal cancer Altered regulation of the clock gene machinery is involved in carcinogenesis and ARNTL plays a key role in the transcription-translation feedback loop driving cellular functions. In this study we have evaluated ARNTL mRNA expression levels in colorectal cancer. We found that the expression level of the clock gene ARNTL is down-regulated in colorectal cancer tissue, is associated with clinical, pathological and molecular features of disease and influences survival in colorectal cancer patients.
Since 2022, Contract Professor for teaching of the Chronobiology Course as part of the Elective Didactic Activity at the Department of Medical and Surgical Sciences, Master's Degree Course in Medicine and Surgery of the University of Foggia, Foggia, Italy Since 2022 National Scientific Habilitation (Ministry of Education – Italy, Bando D.D. 553/2021 competitive sector 05/F1 Applied Biology (BIO/13) - Full Professor Since 2019 National Scientific Habilitation (Ministry of Education – Italy, Bando D.D. 1532/2016) competitive sector 05/E2 Molecolar Biology (BIO/11) - Associate Professor Since 2018 Visiting Scientist and Doctorate in Medicine, Pathology and Gerontology (Honoris Causa) at the Saint Petersburg Institute of Bioregulation and Gerontology, Saint Petersburg, Russia 2014-2017 Visiting Scientist at the University College London, lnstitute for Liver and Digestive Health, Division of Medicine, The Royal Free Hospital, London, United Kingdom 2011-2013 Visiting Scientist at the Institute of Hepatology, Foundation for Liver Research and Birkbeck College, University of London, London, United Kingdom. Since 2011 Senior Scientist of the Chronobiology Laboratory at the IRCCS Scientific Institute and Regional General Hospital “Casa Sollievo della Sofferenza” San Giovanni Rotondo (FG), Italy. 2003-2005 Contract Professor of Medical Oncology at the School for Obstetrics at the University of Foggia, Foggia, Italy. Since 1993 Visiting Scientist at the Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy Since 1991 attending Physician and Researcher at the Department of Medical Sciences, Division of Internal Medicine, IRCCS Scientific Institute and Regional General Hospital “Casa Sollievo della Sofferenza” San Giovanni Rotondo (FG) Italy. 1987-2012 collaboration with the Chronobiology Laboratories, University of Minnesota, Minneapolis, USA .Board of Internal Medicine, University of Florence, Italy, in 1993. Medical School Diploma, University of Florence, Italy, in 1987 (summa cum laude)
Noemi Rotllan obtained her B.Sc and MS in Biology in 1996 from the University of Barcelona. She also earned her Ph.D. degree in 2008. She did her 1st postdoctoral trainee in Dr. Edward Fisher laboratory at NYU with a Fulbright fellowship. Following that, she did a 2nd postdoctoral trainee in Dr. Carlos Fernández Hernando laboratory at NYU and Yale University, where she was an Associate Research Scientist. Dr.Rotllan was also a recipient of the Scientific Development Grant award from the AHA. In 2019 she moved back to Barcelona where she starts her own laboratory with the prestigious Ramon y Cajal fellowship award. Her research interests are focused mainly on the role of new microRNAs in regulating lipoprotein metabolism and the progression of atherosclerosis and to use an innovative therapeutic approach for targeting miRNAs in vivo.
Institut dInvestigació Biomèdica Sant Pau (IIB Sant Pau), Spain
Dr. Sonia Benitez. Bachelor in Biochemistry (1996) and PhD in Biochemistry (2002) by Autonomous University from Barcelona. From 1996 in the Cardiovascular Biochemistry Group, Institut Investigació Biomèdica Sant Pau (IIB Sant Pau); Hospital de la Santa Creu i Sant Pau, Barcelona. Senior Investigator Website: http://www.recercasantpau.cat/grup/bioquimica-cardiovascular.
Imagery Unit, Department of Platforms and Technology Research, French Armed Forces Biomedical Research Institute, France
French Armed Forces Biomedical Research Institute, IRBA 1, place Général Valérie André BP 73 ; 91223 Brétigny sur Orge, France Field of interest: in particular the characterization of in situ macrophages and the analysis of the communication between different cells in the context of tissue regeneration, with special emphasis on the study of cytokine-cytokine receptor interactions in situ.
Department of Chemistry and Biomolecular Sciences, John L. Holmes Mass Spectrometry Facility, Faculty of Science, University of Ottawa, Canada
Zoran Minic received his Ph.D. degree in Plant Biology and Biochemistry at the Université de Paris 11, France, in 1998 and his Habilitation (HDR) in science at the Université de Paris 7, in 2004. He worked as a research associate at the Université de Pierre et Marie Curie (Paris, France) and at the Institut National de la Recherche Agronomique (Versailles and Jouy en Josas, France). After relocating to Canada in 2007, he initially worked as a professional research associate at the University of Saskatchewan. Since 2013, at the University of Regina, he worked as a facility manager responsible for the high-throughput proteomics platform in the Proteomics and Genomics core facility. Since 2017, he has been working as a core facility manager of biological John L. Holmes Mass Spectrometry Facility at the University of Ottawa. He is responsible for the development of large-scale proteomics and metabolomics analysis methodologies using state-of-the-art mass spectrometers. During his research and managerial career, he acquired a strong background in proteomics, metabolomics, system biology, liquid chromatography, and mass spectrometry. He is involving in many collaborative projects with industry and academia. His personal research project is related to using omics approaches to study extracellular vesicles for diagnosis and treatment of cancer. He is the author/co-author of more than 70 academic journal articles, books chapters and patents.
Department of Experimental Medicine, Sapienza University of Rome, Italy
Dr. Giuseppina Catanzaro is a Research Assistant in the Department of Experimental Medicine in Sapienza University of Rome. She received her PhD in Biotechnology from the University of Teramo and pursued her post-doctoral studies in the field of Biochemistry in the laboratory of Prof. Maccarrone. She joined a post-doc in the Bracco Research Center where she was in charge of the biological part of a vast multidisciplinary research project involving cancer cell metabolism, collaborating with the Albeda Research Group in Copenhagen (Denmark) to study the metabolic activity of several cancer cells. Then, she moved in Sapienza University where she has been involved in several projects focused on the molecular and clinical aspects of cancers. Her activity is especially concentrates on defining the role of non-coding RNAs as key molecules in cancer and metabolic diseases, both for their biological functions and for their role as diagnostic, prognostic and predictive biomarkers. She is author of more than 40 original peer-reviewed papers and in the last years she contributed to increase the knowledge about the role of microRNAs, with a special focus on pediatric neuro-oncology. For her research, she won many prestigious awards, such as the Ricerche Oncologiche di Base award in 2018 and in 2022, and a special Mention for the best video for EXPO 2020 Dubai for the call “Beyond borders: La conoscenza unisce le persone” sponsored by Fondazione Bracco.
microRNAs, pediatric brain tumors, solid tumors, metabolic diseases
Servicio de Dermatología, Head of Hospitalization and Emergencies in Dermatology, Hospital Ramon y Cajal Madrid, Spain
Prof Montserrat Fernández-Guarino is a Specialist in Dermatology since 2008. Trained in Ramón y Cajal Dermatology Service, she obtained the Doctoral Thesis with Cum Laude and was selected as the ""Extraordinary Thesis award"" as the best thesis of the year in Alcala University. Dra Fernández-Guarino is certified in Psychology and has four different Master degrees focused on health assistance as nutrition, pharmacy, rehabilitation and hospital management. Dra Fernández-Guarino is accredited by the National Spanish Education Ministry as a Professor of Medical University (ANECA). She has developed as a Principal investigator and as a collaborator, different investigation research in partnership with industry and in competitive calls in private and public calls. Summary of the present position: -Staff Dermatologist at Hospital Universitario Ramón y Cajal, Madrid (2008-present) -Tutor of Dermatologist residents and residents of other medical specialist (Internal Medicine, Immunology, Allergy). -Coordinator of Emergencies in Dermatology of the Hospital. -Head of the Hospitalization in Dermatology. -Consultant of investigation in Photodynamic therapy. - Part-time private practice in General, Dermatology in my own Clinic (Madriderma) Main interests General dermatology, clinical dermatology, photobiology, phototherapy, photodynamic therapy, lasers, complex dermatology, inflammatory dermatology, emergencies in dermatology, photodynamic therapy, wound healing
Université de Reims Champagne-Ardenne, EA 4691 BIOS, 51 Rue Cognacq Jay, France
Frédéric VELARD, PhD-HDR, Research Engineer in the BIOS laboratory from University of Reims Champagne-Ardenne. Forty years old, he defended his PhD thesis in 2009 (INSERM UMRS-926, Reims). His work focused on acute inflammation control through the effect of zinc-doped ceramics. Especially, he has worked on PMNs response to HAp particles and the importance of IL-8 chemokine production in aseptic loosening of orthopedic implants. During post-doctoral fellowship in INSERM UMRS-606, Paris, he has worked on arthritis and osteoarthritis development due to chondrocytes apoptosis both in inflammatory and hypoxic environment. He joined his current laboratory in 2011 (getting his tenure position in 2014), to develop programs in close relation with the understanding of inflammatory processes in bone tissue regeneration and physiology. Author of 53 indexed publications he presented his works in more than 100 national and international conferences. He supervised 8 PhD students (4 former, 4 co-supervised on-going). F. Velard coordinated several local and national institutional research programs as well as collaborative contracts with industrial partners. Nowadays, he works on programs aiming at tools development to enhance bone regeneration, ranging from i) bone substitute conceptualization through ii) deepen understanding of cells deficient maturation and communication in bone thanks to rare disease models, in order to find new ways to promote bone homeostasis for all patients who suffers from hard tissues alterations.
Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Australia
Expert in Nano-biotechnology, Encapsulation & Targeting of Bioactive agents with substantial number of publications, 12 Patents, 5 Books & several Book-chapters. Author of the first book on Nanoliposomes; completed many industrial research projects, developed methods (e.g. “Mozafari Method”) for large-scale manufacture of controlled-release systems without using toxic agents. Recently introduced a novel technology for the encapsulation and delivery of bioactive material called "Tocosome".
Understanding the physiology of teeth-derived stem cells towards regenerative medicine purposes
Sessions
S2. Molecular Mechanisms of Neurodegeneration
S3. Extracellular Vesicles for Biomarker Discovery
S4. Medicinally Active Plants and Phytochemicals
S5. Wound Healing
S6. Musculoskeletal Tissue Regeneration
S7. Nutraceuticals as Adjuvant Therapeutics
S8. Frontiers of biomedicine in SARS-CoV-2
S9. Gastrointestinal Cancer
S10. Immune System, Tumor Immunology and Autoimmune Disease
Instructions for Authors
Submissions should be made by authors online by registering with www.sciforum.net and using the "New Submission" function once logged into the system.
Note: Institutional email address is requested especially for the corresponding author. Please submit the abstract with the institutional email address, the submissions with email addresses like gmail.com, 163.com, hotmail.com, qq.com, etc., will not be reviewed.
1. Scholars interested in participating in the conference can submit their abstract (about 200–300 words) online on this website until 5 January 2023.
2. The Conference Committee will notify the acceptance of the abstract by 16 January 2023.
3. In case of acceptance, authors will be asked to submit their manuscript (short proceedings paper, 3–6 pages) before 6 February 2023. Optionally, authors of accepted abstracts will be able to submit a poster, a slides presentation (in PDF) and/or a short video presentation (max. 3–5 minutes) as supporting material of the paper. Authors will receive a notification about the acceptance of their papers by 17 February 2023.
Note: All submissions will be reviewed using the powerful text comparison tool iThenticate. This procedure aims to prevent scholarly and professional plagiarism. Submissions will then be peer-reviewed by conference committees based on originality/novelty, quality of presentation, scientific soundness, interest to the readers, overall merit and English level. After the conference, all submissions will be published on sciforum.net, and only the proceeding paper (3-6 pages) will be published in the MDPI Medical Sciences Forum journal (ISSN 2673-9992)..
Note: Publication of proceedings paper is free of charge.
Before publication, Medical Sciences Forum journal (ISSN 2673-9992). journal will check the plagiarism issue again. Submissions with a lack of novelty will not be published in the journ
4. The open access journal Biomedicines (Impact Factor 4.757) will publish a dedicated conference Special Issue "Selected Papers in the 2nd International Electronic Conference on Biomedicines (ECB 2023)". Conference participants are encouraged to submit a full paper to the dedicated Special Issue and will receive a 20% discount on the Article Processing Charges (APC).
Note: The submission to the Biomedicines journal is independent of the conference proceedings and will follow the usual process of the journal, including peer-review, APC, etc.
Proceedings papers must be prepared in MS Word using the Medical Sciences Forum template (See below) and should be converted to PDF format before submission. The manuscript should count at least 3 pages (incl. figures, tables and references) and should not exceed 6 pages. Carefully read the rules outlined in the 'Instructions for Authors' on the journal website and ensure that your manuscript submission adheres to these guidelines.
Manuscripts for the proceedings issue must have the following organization:
- Title
- Full author names
- Affiliations (including full postal address) and authors' e-mail addresses
- Abstract
- Keywords
- Introduction
- Methods
- Results and Discussion
- Conclusions
- (Acknowledgements)
- References
Authors are encouraged to prepare a presentation in PowerPoint or similar software, to be displayed online along with the manuscript. Slides can be prepared the same way as for any traditional conference. They should be converted to PDF format before submission.
Authors are requested to submit video presentations with extended submissions. The video should be no longer than 3–5 minutes and prepared with one of the following formats: .mp4 / .webm / .ogg (max size: 250Mb). It should be submitted with the full manuscript before 11 January 2023 (full submission deadline).
The accepted submissions will be shown on the conference submission page of ECB 2023 which will be open after the conference starts. Here is an example of ECB 2021: https://ecb2021.sciforum.net/#submissions.
Moreover, authors that submitted presentations will have the chance to be invited to hold a presentation in the Live Session (15 mins). The live streaming platform we are using is Zoom. This is a unique way of presenting your paper and discussing it with peers from all over the world.
Note: Exhibitors who attend/register for the Webinar are considered to agree that their images and presentation content will be publicly released.
Posters will be available on this conference website during and after the event. Like papers presented on the conference, participants will be able to ask questions and make comments about the posters. Posters can be presented without an accompanying proceedings paper.
After acceptance, please upload a copy of the proceedings/abstract as a PDF and word document, in the corresponding fields, and upload the Poster PDF in the field "Presentation PDF (optional)".
1) The poster should be in PDF format
2) The minimum size for images is 148 mm × 210 mm (horizontal × vertical) at 300 dpi.
3) The content of the poster should be a comprehensive presentation of your accepted submission.
4) No copyright issues with any elements in the poster.
For detailed instructions on how to submit a poster, please contact us at ecb@mdpi.com.
All authors must disclose all relationships or interests that could inappropriately influence or bias their work. This should be conveyed in a separate "Conflict of Interest" statement preceding the "Acknowledgments" and "References" sections at the end of the manuscript. If there is no conflict, please state "The authors declare no conflict of interest." Financial support for the study must be fully disclosed under the "Acknowledgments" section.
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe that authors should retain the copyright to their scholarly works. Hence, by submitting a communication paper to this conference, you retain the copyright of your paper, but you grant MDPI the non-exclusive right to publish this paper online on the Sciforum.net platform. This means you can easily submit your paper to any scientific journal at a later stage and transfer the copyright to its publisher (if required by that publisher).
List of accepted submissions (63)
Id | Title | Authors | Presentation Video | Poster PDF | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
sciforum-066873 | Polyherbal Oral Spray for Instant Mouth Refreshing | , | N/A | N/A |
Show Abstract |
||||||||||||||||||||||||||||||||||||
In today’s busy lifestyle, people are experiencing constant shortage of time for their personal care. Focus on personal health and hygiene has reduced to the significant extent. In such situation, health and hygiene of the people are continuously downgrading due to lack of attention towards it. As the solution of such situations, market is full of many instantly acting products containing harmful chemicals and ingredients. Mouth health and hygiene is of prime importance as it is the main gateway of food and also for verbal communication. Tackling the increasing problems related to the health and hygiene of oral cavity and also emerging issues due to excessive use of instant acting products for it is the need of the hour. Herbal formulations are proven treatment options that can deal with such situations without any untoward side effects. We had studied many traditionally used natural items to screen a few of the potent ingredients to formulate an oral spray. Developed polyherbal spray formulation using Clove oil, Peppermint oil, Fennel oil, Piper Betel oil and Cardamom oil was evaluated for various basic parameters. As all of the above herbal ingredients are already proven their activities for maintaining and improving oral hygiene and health, the final product was not evaluated for specific activities. Moreover it don’t require additional facilities like In the nutshell, developed polyherbal spray was found to be a probable alternative for instant mouth refreshning product dealing with majority of oral health and hygiene issues, especially foul smell. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-069882 | Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis | , , | N/A | N/A |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Background: Multiple sclerosis (MS) is a neuroinflammatory and neurodegenerative disease characterized by myelin damage followed by axonal and ultimately neuronal loss. The etiology and physiopathology of MS are still elusive, and no fully effective therapy is yet available Objectives: We investigated the role in MS of autophagy (physiologically, a controlled intracellular pathway regulating the degradation of cellular components) and of mitophagy (a specific form of autophagy that removes dysfunctional mitochondria). Methods: Our study has been performed by using in vitro, ex vivo and in vivo model of MS. Furthermore, experiments have been also conducted in human biofluids obtained from healthy and MS-affected individuals Results: Three main findings emerge from the present work. First, autophagy and its selective forms occur in MS patients and in experimental models of MS; second, these phenomena play a causal role in MS be-cause their inhibition prevents myelin loss; third, two clinically used drugs can inhibit autophagy, prevent demyelination, induce remyelination, and revert MS behavioral deficits Conclusion: Our findings suggest to repurpose Food and Drug Administration–approved drugs for the treatment of MS, at least in patients with MS variants that are more closely modeled by CPZ, like type III and IV. Such compounds may accelerate recovery from a demyelinating attack and prevent relapses. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-069847 | GC-MS based Metabolite profiling, and anti-inflammatory activity of Aqueous extract of Myrica esculenta through In vitro and In-Silico approach. | , , , , , , , , , , , , | N/A |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
The present study was to determine the anti-inflammatory activity of aqueous extract of bark and root of Myrica esculenta and their active phytoconstituents through In-Vitro and In-Silico studies. The bioactive phytoconstituent of Myrica esculenta determined by GC-MS spectroscopy techniques. After that total phenolic and flavonoid content of both bark and root extract was determined. Furthermore, In-vitro anti-inflammatory activity was determined in both extracts. The molecular docking analysis determined the binding affinity of bioactive compounds against inflammatory proteins COX-1, COX-2, IL-10, and TNF-α. The present study revealed bark extract of Myrica esculenta has the highest total phenolic and flavonoid content compared with root extract (553.44±18.38mg GAE/g equivalent and 336.02±8.04mg quercetin/g equivalent respectively). Similarly, the bark extract showed good inhibitory activity with 5-LOX and HYA assay (IC50 11.26±3.93 and 21.61±8.27 µg/mL respectively), but in 15-Lox inhibitory assay root extract showed the highest inhibitory activity, IC50 16.95±5.92 µg/mL. The Docking result showed that myrecitin, Arjunolic acid, and myricanone have the highest binding affinity with all inflammatory proteins in respective order: myrecitin>arjunolic acid>celecoxib>myricanone>myricitrin>3-epi-ursonic acid. The MD simulation of COX-1 and myrecitin showed the highest stability and low deviation at 310K through RMSD values (1.07-2.3 Å) as compared with COX-1 and myricitrin (0.193-1.885 Å) and TNF-α and myricanone (1.377 to 3.457Å) respectively when analyzed at 100 ns time frame. Extract and their active constituents showed good anti-inflammatory activity. Further study is essential to define their mechanism of action. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-069480 | Signature garlic phytochemical as a potential anti-candidal candidate targeting virulence factors in Candida albicans | , , | N/A | N/A |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Anti-microbial resistance to presently available antifungal medications, as well as an increase in their toxicity, is becoming a severe concern throughout the world. It is necessary to investigate innovative, more effective medications especially derived from medicinally active plants with lesser chances of side effects. Allyl methyl sulfide (AMS) is an organosulfur derived from garlic oil which is responsible for typical garlic odour is explored for its therapeutic potential against Candida albicans. The effect of AMS on major virulence factors has been studied in Candida albicans reference strains, with MIC and MFC values reported to be 200 µg/ml and 400 µg/ml, respectively. Fungal growth in C. albicans was entirely inhibited at their respective MIC values, as demonstrated by growth curve and time kill kinetics experiments. In C. albicans, AMS treatment also reduces attachment to buccal cell epithelial tissues as measured microscopically. After treatment with AMS, C. albicans' release of extracellular proteinases, phospholipases, and biofilm formation were significantly inhibited. AMS exhibited little toxicity to human red blood cells (RBCs), indicating that it might be a feasible alternative to commonly used antifungal medications. More research is needed to determine its mechanism of action and precise target areas. The current work should be supported by molecular in silico and in vivo research. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-069467 | Silybin, the main active component of Silybum marianum, affects blood coagulation: an in vitro pilot study | , , , , | N/A | N/A |
Show Abstract |
||||||||||||||||||||||||||||||||||||
The health-promoting properties of Silybum marianum have been acknowledged since antiquity. This plant is credited with substantial hepatoprotective properties and is also protective in cardiovascular diseases, diabetes mellitus, and neurodegeneration, mainly for its anti-inflammatory and antioxidant effects. Only a few experimental studies have described the impact of Silybum marianum extract on the blood coagulation process; furthermore, these data are unsatisfactorily fragmented and need to be supplemented to understand the plant’s properties better. The predominant biologically active flavonolignan extracted from Silybum marianum is silybin, a mixture of two diastereomers, silybin A and silybin B, in approximately equimolar ratio. This study investigated the effect of silybin on the fundamental laboratory parameter for blood coagulation, namely prothrombin time (PT), an assay used to assess the extrinsic and common coagulation pathways. |
Event Awards
To acknowledge the support of the conference esteemed authors and recognize their outstanding scientific accomplishments, we are pleased to announce that the conference will provide one Best Paper Award and one Best Presentation Award.
The Awards
Number of Awards Available: 1
The Best Paper Award is given to the paper judged to make the most significant contribution to the Conference.
Number of Awards Available: 1
The winner of Best Presentation Award is selected by the Scientific Committee after evaluation of all selected talks presented during the conference.
Terms and Conditions:
On behalf of the chairs of ECB 2023, we are pleased to announce the winner of the Best Paper Award:
Sciforum-069152, "Reprogrammed CD8+ T-Cells Isolated from the Spleen Increase the Number of Immune Cells with Antitumor Activity and Has Antimetastatic Effect on Lewis Lung Carcinoma in C57BL/6 Mice"
Evgenii Skurikhin, Olga Pershina, Angelina Pakhomova, Natalia Ermakova, Darius Widera, Edgar Pan, Lubov Sandrikina, Mariia Zhukova, Lena Kogai, Nikolai Kushlinskii, Sergey Morozov, Aslan Kubatiev, Alexander Dygai
The Award consists of 500 CHF and a certificate.
On behalf of the chairs of ECB 2023, we are pleased to announce the winner of the Best Presentation Award:
Sciforum-067791, "EXPERIMENTAL IDENTIFICATION OF ABERRANLY EXPRESSED LONG NON-CODING RNAS IN BREAST CANCER"
Irina Pronina, Svetlana Lukina, Vitaly Loginov, Aleksey Burdennyy, Tatiana Kazubskaya, Eleonora Braga, Elena Filippova
The Award consists of 500 CHF and a certificate.
Conference Secretariat
Ms. Maria Li
Ms. Suzie Song
Ms. Alethea Liu
MDPI Branch Office, Wuhan
E-Mail: ecb@mdpi.com
Sponsoring Opportunities
For information regarding sponsoring opportunities, please contact the conference secretariat.
S1. RNA Processing and Human Diseases
Session Chair
Dr. Giuseppina Catanzaro, Sapienza University of Rome, Rome, Italy
S2. Molecular Mechanisms of Neurodegeneration
Session Chair
Dr. Masaru Tanaka, University of Szeged (ELKH-SZTE), Szeged, Hungary
S3. Extracellular Vesicles for Biomarker Discovery
Session Chair
Dr. Zoran Minic, University of Ottawa, Ottawa, Canada
Show all published submissions (2) Hide published submissions (2)
Submissions
List of Papers (2) Toggle list
S4. Medicinally Active Plants and Phytochemicals
Session Chair
Prof. Dr. Shaker A. Mousa, Albany College of Pharmacy and Health Sciences, Rensselaer, USA
S5. Wound Healing
Session Chair
Dr. Stefano Bacci, University of Florence, Florence, Italy
S6. Musculoskeletal Tissue Regeneration
Session Chair
Dr. Krisztina Nikovics, French Armed Forces Biomedical Research Institute, Brétigny-sur-Orge, France
S7. Nutraceuticals as Adjuvant Therapeutics
Session Chair
Prof. Dr. Ciro Isidoro, Università del Piemonte Orientale, Novara, Italy
Show all accepted abstracts (1) Hide accepted abstracts (1)
List of Accepted Abstracts (1) Toggle list
S8. Frontiers of biomedicine in SARS-CoV-2
Session Chair
Dr. Sílvia Andreia Bento da Silva Sousa, Instituto Superior Técnico, Lisbon, Portugal
S9. Gastrointestinal Cancer
Session Chair
Dr. Ryota Niikura, Gastroenterological Endoscopy, Tokyo Medical University
S10. Immune System, Tumor Immunology and Autoimmune Disease
Session Chair
Dr. Jitka Petrlova, Department of Clinical Sciences, Division of Dermatology and Venereology, Lund University, Sweden